U.S. Oil and Gas Stock News

Medpace Holdings, Inc. recently reported second-quarter 2026 results showing higher sales and net income than a year earlier, and it completed a US$1.57 billion share repurchase program that retired 17.25% of its shares. Soon after, the company raised its 2026 outlook, now projecting revenue between US$2.81 billion and US$2.89 billion and net income of US$494 million to US$514 million, signaling management’s confidence in current business trends. Next, we’ll examine how Medpace’s upgraded...

SiriusPoint Ltd. has reported past second-quarter 2026 results showing revenue of US$744.1 million versus US$748.2 million a year earlier, with net income rising to US$68.6 million and diluted earnings per share from continuing operations increasing to US$0.58 from US$0.50. Despite slightly lower revenue, SiriusPoint delivered higher profitability and has also strengthened its leadership bench with the appointment of a new Chief Operating Officer to drive technology and operational...

AvalonBay Communities has delivered a 15.1% total return over the past 3 years, yet the valuation picture is not straightforward. An intrinsic value estimate based on a Discounted Cash Flow (DCF) approach points to upside, while broader checks look more mixed. At the same time, market-based multiples suggest the stock is trading at about the right level, which puts extra focus on which lens investors choose to rely on. Over the last 3 years, AvalonBay Communities has returned 15.1%, which is...

Erie Indemnity (ERIE) is set to report Q2 2026 results after the market closes on July 30, 2026. This scheduled earnings release gives investors fresh information to reassess the insurance services stock. See our latest analysis for Erie Indemnity. Over the past week Erie Indemnity has seen a 7 day share price return of 17.87% and a 90 day share price return of 13.53%. However, the year to date share price return is down 10.53% and the 1 year total shareholder return has declined 28.17%. This...

Clorox stock is trading at about US$99.63 after a difficult few years for shareholders, yet both the Discounted Cash Flow (DCF) intrinsic value estimate and the earnings multiples currently point to the shares looking inexpensive rather than stretched. Clorox has delivered a decline of roughly 29.1% over the past 5 years, which means the share price has lagged while the latest valuation checks now suggest more supportive pricing. Expectations that Clorox can continue to convert earnings into...

In July 2026, Dynex Capital reported second-quarter 2026 results showing net income of US$180.79 million, with basic and diluted earnings per share from continuing operations of US$0.80. An unusual aspect of these results is that first-half 2026 net income of US$100.43 million trails the second-quarter figure alone, highlighting quarterly volatility. We’ll now consider how this earnings volatility, particularly the stronger second quarter performance, may influence Dynex Capital’s broader...

Varonis Systems walked into this earnings season on a strong run, with the stock up sharply over the past three months. That momentum snapped hard. Shares fell 9% to US$40.65 in the first full session after results, even though the headline was not about a demand problem. The real story is the margin picture. Varonis reported US$180.0m in revenue with a non GAAP gross margin of 77.7% and only a thin non GAAP operating income of US$3.7m. For a high price to sales cyber security stock, that...

CRH (NYSE:CRH) has drawn investor attention after recent share price pressure, with the stock down 8.4% over the past month and 21.1% year to date, despite positive annual revenue and net income growth. See our latest analysis for CRH. For context, CRH's share price is currently US$99.71 and has fallen 21.1% year to date. The stock still records a 4.5% one year total shareholder return and a 117.2% five year total shareholder return, suggesting recent momentum has faded even as longer term...

Fed Chairman Kevin Warsh’s decision to hold rates steady despite inflation above target has thrown fresh attention on financial stocks that live and breathe interest rate expectations. Longer term yields have moved higher and market odds now lean toward rates staying unchanged at the next meeting. That combination can reshape funding costs, loan demand, investment returns and capital positions for banks and insurers. This article walks through how that backdrop links to our Financial Sector...

AeroVironment, Inc. recently announced that long-serving board member Stephen Page will retire at the end of his current term in September 2026, while the company also entered a teaming agreement with Applied Intuition to integrate its Acuity ISR/Strike software into the Mayhem 10 launched effects system for autonomous military drone operations. This combination of board transition and deeper integration of third-party autonomy software into AeroVironment’s open, vendor-agnostic launched...

TPG RE Finance Trust went into this earnings print with a stock that has drifted lower in recent weeks and then dropped another 3.9% to about US$8.21 as investors reacted. The headline, however, is not about the income statement. It is the balance sheet. Management used the quarter to lock in a US$400 million Term Loan B, add a long dated revolver and extend secured facilities, all while keeping overall funding costs and leverage broadly in line. For a commercial mortgage REIT, that kind of...

Matador Resources (MTDR) is drawing attention after shifting expectations around its upcoming June 2026 quarter, with forecasts for higher earnings and revenue set against a recent downward revision to the consensus EPS estimate. See our latest analysis for Matador Resources. At a share price of $48.66, Matador Resources has seen a 12.22% year to date share price return. However, the 1 year total shareholder return is slightly negative at 2.08%, with the 3 year total shareholder return also...

In the second quarter ended June 30, 2026, KeyCorp reported net interest income of US$1,250 million and net income of US$509 million, up from US$1,141 million and US$425 million a year earlier, alongside net loan charge-offs rising to US$115 million from US$102 million. This combination of higher earnings per share and modestly higher credit losses points to stronger core profitability while risk costs inch higher. We’ll now examine how this earnings improvement, particularly the rise in net...

Astera Labs stock has delivered a 93.8% return over the past year. After that kind of move, the current valuation now looks closer to fair value, with the intrinsic value estimate from a Discounted Cash Flow (DCF) model and market-based multiples both pointing to pricing that is about in line with fundamentals rather than clearly cheap. Over the last 12 months Astera Labs is up 93.8%, so the share price already reflects a lot of optimism about the company. Expectations for continued revenue...

RenaissanceRe Holdings Ltd. has reported past second-quarter 2026 results, with revenue of US$2,768.6 million and net income of US$663.08 million, alongside six-month diluted earnings per share from continuing operations of US$21.94 that exceeded the prior-year period. Over the same timeframe, the company also completed a substantial share repurchase program of 3,425,600 shares for US$995.69 million, returning a meaningful portion of capital to shareholders while shrinking its equity...

Earlier this week, the European Medicines Agency’s Committee for Medicinal Products for Human Use adopted a positive opinion backing Gilead Sciences’ Trodelvy in combination with Merck’s Keytruda as a first-line treatment for certain adults with unresectable locally advanced or metastatic triple-negative breast cancer whose tumors express PD-L1 with a combined positive score of at least 10. This recommendation, grounded in Phase 3 ASCENT-04/KEYNOTE-D19 data showing a materially lower risk of...

NovoCure stock is coming off a very difficult five year stretch, with the share price down about 90%, yet the latest valuation checks still lean toward the shares looking cheap on several measures. That contrast, alongside fresh company developments in cancer therapies, is what investors are weighing now. Over the past five years, NovoCure shares have declined about 90%. As a result, any sign of a sustainable business recovery can have an outsized impact on how the market prices the...

Sales update puts fresh focus on Interparfums stock Interparfums (IPAR) has drawn fresh attention after reporting consolidated net sales of US$341 million for the second quarter and US$686 million for the first half of 2026, compared with the same periods a year earlier. See our latest analysis for Interparfums. Following the sales update, Interparfums shares trade at US$127.03, with a 30 day share price return of 15.51% and a year to date share price return of 48.68%. This points to strong...

US LNG exports are reshaping global gas flows, and that shift is starting to show up in individual stocks. As Louisiana grows into a major LNG hub and long term export contracts with Europe expand, some companies appear well placed for higher fee based volumes, while others face pressure from changing trade routes and pricing. This article walks through three stocks exposed to this news, with two that could benefit from the US export build out and one that may face headwinds, to help you...

OPKO Health (OPK) moved into focus after its Q2 2026 earnings report and guidance, which showed revenue of US$163.58 million and a sharply lower net loss compared with the prior year period. See our latest analysis for OPKO Health. OPKO Health shares have been volatile around the earnings release, with the 1-day share price return falling 17.27% after hitting a new 52-week high. However, the 90-day share price return of 24.09% and 1-year total shareholder return of 6.64% suggest momentum has...

Rogers stock slipped about 2% today, yet the quarter just reported looks more like a repair job gaining traction than a thesis breaking down. This is a company often treated as a high multiple materials pure play with a rich P/E and big expectations built into the story. The headline today is simple: profitability is rebuilding faster than the share price suggests, with Q2 basic earnings per share at roughly three times Q1 and revenue at about $216.8m. The gap between that improving income...

Earlier this week, IDEAYA Biosciences announced that it has begun Part 2 monotherapy expansion in its Phase 1/2 trial of IDE892, a highly selective PRMT5 inhibitor for MTAP-deleted solid tumors including non-small cell lung cancer and pancreatic ductal adenocarcinoma, at exposures expected to provide 24‑hour EC90 target coverage. An interesting element of this update is IDEAYA’s plan to position IDE892 as a combination backbone across MTAP-deleted cancers, including collaborations with...

Compañía de Minas BuenaventuraA (BVN) moved into focus after the company released detailed second quarter 2026 sales and production figures, alongside updated full year guidance for key metals output. See our latest analysis for Compañía de Minas BuenaventuraA. The updated production guidance landed against a mixed trading backdrop for Compañía de Minas BuenaventuraA, with the share price down 5.83% over the past week but up 5.70% year to date, while the 1 year and multi year total...

Sound Financial Bancorp stock barely flinched today, slipping just 0.5%, even though the quarter delivered a clear earnings jolt. Basic earnings per share for Q2 came in close to US$1, backed by revenue a little above US$11 million. For a small regional bank, that kind of profit engine can matter more than a fractional price move. The real story is margin power. Over the last twelve months, net profit margin moved into the high teens and earnings climbed sharply, yet the P/E sits at 14.1x...